Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Foghorn Therapeutics (FHTX) Accumulated Depreciation & Amortization (2019 - 2025)

Foghorn Therapeutics has reported Accumulated Depreciation & Amortization over the past 7 years, most recently at $3.3 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 6.79% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, up 6.79%, while the annual FY2025 figure was $3.3 million, 6.79% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $3.3 million at Foghorn Therapeutics, up from $900000.0 in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $3.5 million in Q4 2023 and troughed at $700000.0 in Q3 2024.
  • A 5-year average of $1.7 million and a median of $1.6 million in 2021 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 700.0% in 2021 and later tumbled 62.5% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $3.2 million in 2021, then increased by 3.12% to $3.3 million in 2022, then increased by 4.58% to $3.5 million in 2023, then dropped by 9.59% to $3.1 million in 2024, then grew by 6.79% to $3.3 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for FHTX at $3.3 million in Q4 2025, $900000.0 in Q3 2025, and $1.7 million in Q2 2025.